NCT07014618 Navigator-Assisted Hypofractionation (NAVAH) on Radiation Therapy Completion in Breast Cancer and Prostate Cancer
| NCT ID | NCT07014618 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Oklahoma |
| Condition | Breast Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 420 participants |
| Start Date | 2025-10-16 |
| Primary Completion | 2029-10 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 420 participants in total. It began in 2025-10-16 with a primary completion date of 2029-10.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The purpose of this clinical trial is to evaluate radiation therapy (RT) completion rates among underrepresented cancer populations using qualitative measurements. Additionally, the study aims to assess the impact of patient navigators on supporting patients through their radiation care, as well as their influence on adherence to standard of care treatment modalities.
Eligibility Criteria
Inclusion Criteria: * Subjects must have histologically or cytologically confirmed Breast or Prostate Cancer. * Subjects must be 18 years of age or older. This study requires informed consent by the subject. * Subjects must be of African American race, Native American race, or Hispanic ethnicity. * Subjects scheduled to undergo RT for Cancer Treatment. * Subjects must have the ability to understand and the willingness to sign a written informed consent document. Exclusion Criteria: * Subjects NOT of African American race, Native American race or Hispanic ethnicity. * Subjects WITHOUT histologically/cytologically confirmed Breast or Prostate Cancer. * Subjects younger than 18 years old.
Contact & Investigator
Shearwood McClelland III, MD
PRINCIPAL INVESTIGATOR
OU Health Stephenson Cancer Center
Frequently Asked Questions
Who can join the NCT07014618 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Breast Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07014618 currently recruiting?
Yes, NCT07014618 is actively recruiting participants. Contact the research team at SCC-IIT-Office@ouhsc.edu for enrollment information.
Where is the NCT07014618 trial being conducted?
This trial is being conducted at Oklahoma City, United States.
Who is sponsoring the NCT07014618 clinical trial?
NCT07014618 is sponsored by University of Oklahoma. The principal investigator is Shearwood McClelland III, MD at OU Health Stephenson Cancer Center. The trial plans to enroll 420 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.